Publication:
Inherited burden for disease predisposition in diverse populations

dc.contributor.coauthorKayaalp, B.
dc.contributor.coauthorKars, M.E.
dc.contributor.coauthorItan, Y.
dc.contributor.coauthorCasanova, J.L.
dc.contributor.coauthorÖzçelik, T.
dc.contributor.departmentSchool of Medicine
dc.contributor.departmentNDAL (Neurodegeneration Research Laboratory)
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.kuauthorBaşak, Ayşe Nazlı
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteLaboratory
dc.date.accessioned2026-07-02T07:03:21Z
dc.date.available2026-03-27
dc.date.issued2026
dc.description.abstractWe leveraged allele frequencies from gnomAD, Regeneron Genetics Center Million Exome and Turkish Variome for 4591 disease genes from PanelApp and OMIM, and identified 97,135 pathogenic and 478,263 likely pathogenic variants using an American College of Medical Genetics and Genomics-based classifier. This expanded pathogenic and likely pathogenic variants nearly six-fold. On average, an individual is born with 4.70 pathogenic or likely pathogenic variants, of which 1.66 are compatible with a Mendelian condition at the genotype level; 1 in 11 has an actionable genotype, and 382 genes are candidates for carrier screening. A genome-first approach revealed the likelihood of having a genotype compatible with disease in 13 ICD-10 disease groups, for example, congenital (1 in 2.70), musculoskeletal/connective (1 in 3.00) and blood/immune (1 in 3.07 individuals). Evidence-based genetic epidemiology demonstrates the potential of personalized medicine for the implementation of early preventive measures and incentivization of lifestyle changes to enhance healthspan and lifespan.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipWe gratefully acknowledge \u0130clal B\u00FCy\u00FCkdevrim \u00D6z\u00E7elik, Nezahat Do\u011Fan and Ramazan Arda \u0130nan for their invaluable contributions. ANB expresses her heartfelt gratitude to Suna \u0130nan and \u0130pek K\u0131rac for their vision, devotion, and dedicated mentorship throughout these studies and to Ko\u00E7 University Research Center for Translational Medicine for the inspiring research facilities created. This study was funded by a grant from the Leducq Foundation, Suna and Inan Kirac Foundation and Ko\u00E7 University. The Turkish Academy of Sciences supported this work. B.K. is the recipients of fellowship 2211-A National Doctorate Scholarship Program of Scientific and Technological Research Council of T\u00FCrkiye (T\u00DCB\u0130TAK) Directorate of Science Fellowships and Grant Programmes. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, The Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI163029, R01AI127564, R01AI095983), the National Center for Advancing Translational Sciences, the NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Fisher Center for Alzheimer\u2019s Research Foundation, the Meyer Foundation, the JPB Foundation, the \u201CInvestissement d\u2019Avenir\u201D program launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM), the Square Foundation, Grandir - Fonds de solidarit\u00E9 pour l\u2019enfance, the Fondation du Souffle, William E. Ford, General Atlantic\u2019s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic\u2019s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation, Paris Cit\u00E9 University, and the Imagine Institute.
dc.description.versionPublished version
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1038/s41525-026-00552-5
dc.identifier.eissn2056-7944
dc.identifier.embargoNo
dc.identifier.issue1
dc.identifier.pubmed41708638
dc.identifier.scopus2-s2.0-105035078499
dc.identifier.urihttps://doi.org/10.1038/s41525-026-00552-5
dc.identifier.urihttps://hdl.handle.net/20.500.14288/32844
dc.identifier.volume11
dc.identifier.wos001726559200001
dc.keywordsGenetic epidemiology
dc.keywordsPrecision medicine
dc.keywordsPathogenic variants
dc.keywordsGenome-first approach
dc.languageeng
dc.publisherNature Research
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofNPJ Genomic Medicine
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectGenetics
dc.subjectHeredity
dc.titleInherited burden for disease predisposition in diverse populations
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublicationd6cdc646-db27-4078-a933-2db6f139bb65
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication20385dee-35e7-484b-8da6-ddcc08271d96
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files